Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase–Src–Paxillin system

Abstract

Introduction: Nonreceptor tyrosine kinases play key roles in the integrin system. Located at the focal adhesions, they consist of large protein complexes through which the cytoskeleton connects to the extracellular matrix. The focal adhesion kinase (FAK)–Src–paxillin complex, a major mediator of the integrin pathway, contributes to cell migration and motility. Its overexpression is increased in children with advanced neuroblastoma (NB), one of the most common malignancies of childhood, with poor survival.

Areas covered: We review the most recent data on FAK–Src–paxillin and their implications in NB, the molecular structure and the regulatory mechanisms of each molecule and their interactions and up-to-date information on their use as the newest biomarkers and their potential use as therapeutic targets in NB.

Expert opinion: Based on the current literature, we hypothesize that combined and concurrent inhibition of the FAK–Src–Paxillin system may result in significant tumor suppression and prevention or delay of metastasis.

Keywords::

• focal adhesion kinase
• neuroblastoma
• paxillin
• small-molecule inhibitors
• Src

Acknowledgments

Chimera 4 inhibitor chemical formula was provided by Matthew Soellner, PhD who also approved this information to be included in our article. The authors would like to thank Diana Winters from the Academic Publishing Office of Drexel University for editing the manuscript. Many thanks to Yanick Vibert, Emilee Flynn, Angeliki Kratimenou and Angelina Ntona for their support in the development of the illustrations.

Notes

This box summarizes key points contained in the article.